DaVita Inc. (NYSE:DVA) Shares Sold by Nisa Investment Advisors LLC

Nisa Investment Advisors LLC lessened its position in shares of DaVita Inc. (NYSE:DVA - Free Report) by 8.6% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 37,034 shares of the company's stock after selling 3,466 shares during the quarter. Nisa Investment Advisors LLC's holdings in DaVita were worth $5,665,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in DVA. Epoch Investment Partners Inc. purchased a new stake in shares of DaVita during the 4th quarter valued at approximately $55,100,000. Invesco Ltd. raised its position in shares of DaVita by 20.9% during the 4th quarter. Invesco Ltd. now owns 1,589,545 shares of the company's stock valued at $237,716,000 after buying an additional 275,284 shares during the period. Iron Triangle Partners LP purchased a new stake in shares of DaVita during the 4th quarter valued at approximately $38,946,000. GAMMA Investing LLC raised its position in shares of DaVita by 14,695.8% during the 1st quarter. GAMMA Investing LLC now owns 234,809 shares of the company's stock valued at $35,919,000 after buying an additional 233,222 shares during the period. Finally, Bridgewater Associates LP raised its position in shares of DaVita by 298.4% during the 4th quarter. Bridgewater Associates LP now owns 239,970 shares of the company's stock valued at $35,888,000 after buying an additional 179,744 shares during the period. Hedge funds and other institutional investors own 90.12% of the company's stock.

DaVita Stock Down 0.7%

Shares of NYSE:DVA traded down $1.03 during trading on Friday, hitting $142.43. The company's stock had a trading volume of 537,608 shares, compared to its average volume of 812,154. The business has a 50 day moving average price of $140.24 and a two-hundred day moving average price of $148.96. The company has a market capitalization of $10.75 billion, a PE ratio of 14.12, a P/E/G ratio of 0.99 and a beta of 1.11. The company has a debt-to-equity ratio of 23.18, a quick ratio of 1.20 and a current ratio of 1.25. DaVita Inc. has a fifty-two week low of $131.76 and a fifty-two week high of $179.60.

DaVita (NYSE:DVA - Get Free Report) last posted its quarterly earnings results on Monday, May 12th. The company reported $2.00 EPS for the quarter, topping the consensus estimate of $1.75 by $0.25. The business had revenue of $3.22 billion during the quarter, compared to the consensus estimate of $3.22 billion. DaVita had a net margin of 6.63% and a return on equity of 176.11%. The company's quarterly revenue was up 5.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.26 earnings per share. As a group, research analysts expect that DaVita Inc. will post 10.76 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on DVA. Wall Street Zen upgraded shares of DaVita from a "hold" rating to a "buy" rating in a report on Friday, April 25th. Truist Financial dropped their target price on shares of DaVita from $170.00 to $164.00 and set a "hold" rating for the company in a report on Monday, May 19th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and two have issued a buy rating to the company's stock. According to MarketBeat, the stock has an average rating of "Hold" and a consensus target price of $164.50.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.